Apollomics, Inc. (NASDAQ:APLM – Get Free Report) was down 4% on Monday . The stock traded as low as $9.45 and last traded at $9.50. Approximately 16,190 shares changed hands during trading, a decline of 83% from the average daily volume of 93,693 shares. The stock had previously closed at $9.90.
Apollomics Stock Down 4.0 %
The business has a 50 day simple moving average of $8.07 and a 200-day simple moving average of $10.48.
About Apollomics
Apollomics, Inc, a clinical-stage biopharmaceutical company, engages in the discovery and development of oncology therapies to harness the immune system and target specific molecular pathways to eradicate cancer. The company’s products portfolio includes Vebreltinib (APL-101), an oral active, highly selective c-Met inhibitor, which is in Phase 2 clinical trials for treatment of non-small cell lung cancer; APL-102, an oral active, small molecule Multiple Tyrosine Kinase Inhibitor, which is in a in a Phase 1 clinical trial to inhibit various kinases that are aberrantly activated in cancer cells; and APL-122, a tumor inhibitor candidate, targeting ErbB1/2/4 signaling pathwaysthat is in Phase 1 dose escalation clinical trials to treat cancers within the brain.
Featured Articles
- Five stocks we like better than Apollomics
- Best Aerospace Stocks Investing
- Super Micro Stock: $7.2M Call Options Signal Big Upside Potential
- How to find penny stocks to invest and trade
- Top 3 Buy-and-Hold Stocks for 2025: Long-Term Winners to Watch
- Profitably Trade Stocks at 52-Week Highs
- D-Wave Stock: Is Quantum Blockchain the Next Big Catalyst?
Receive News & Ratings for Apollomics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Apollomics and related companies with MarketBeat.com's FREE daily email newsletter.
